insights
A discussion with Dr. Shoshana Ungerleider
Last month, we hosted a screening of End Game, the Netflix documentary The New York Times calls a provocative and intimate look at how doctors, nurses and patients cope with death.
What’s it going to take for us to see talking about care at the end of life as a normal wellness practice? -@ShoshUMD #RoadtoEndWell pic.twitter.com/QpTcwZiXI0— MATT…
Read more
insights
A race is underway to develop the next major checkpoint inhibitor that harnesses the innate immune system.
At the forefront is Forty Seven, Inc., a clinical stage immuno-oncology company founded in 2015 that developed out of a lab at Stanford University. The company focuses on targeting the CD47 pathway as a way to engage macrophages — the body’s first responders — in fighting tumors.
Last mo…
Read more
insights
Most people take a medication trusting that it has been studied and approved by an official organization to be effective and safe for everyone. However, for many minority groups, that trust is not a given.
According to Kwaku Owusu, chairman of MATTER startup, Ilerasoft, and founder of Drugviu — an online platform that helps minority populations find medications that will actually work for them…
Read more
insights
CEO Steven Collens shares his thoughts on what the healthcare system will look like 20 years from now. This article was originally published in MedCity News.
One day, a doctor will reach out to you before you even know you’re sick.
That’s the future we see coming to life in the technologies emerging from the healthcare innovation community.
One of the most interesting dynamics we see at MATT…
Read more
insights
Most healthcare startups share a common goal: to improve lives. Whether through a new drug, medical device or digital health platform, most healthcare companies are focused on helping individuals live better and longer.
However, living better doesn’t always mean living longer. Like all healthcare companies, MATTER startup Vynca shares the goal of improving lives, but their focus is on a part o…
Read more